Accelerate alumni



HEPAprint uses genomics to tackle the huge problem of adverse drug reactions. Our vision is to improve patients’ lives and guide the way to safer personalised medicine. Adverse drug reactions (ADR’s) are a major problem causing harm to individuals and are a massive financial burden for healthcare systems worldwide. Annually, it is estimated these ADR’s cause 100,000 preventable deaths and cost an estimated $130 billion in the US alone.

Our solution is a clinical decision-making tool that helps to predict an individual patient’s response to drugs. Each one of us has a unique array of enzymes in our liver that defines how we react to medicines. By cross-correlating genomic data with other big data, we can help predict and prevent a range of adverse drug reactions − ultimately saving money, and more importantly lives!